AP-18 is a novel TRPA1 channel blocker (CHO cells, IC50= 3.1µM; human and mouse cell lines, IC50= 4.5µM). It reduces cinnamaldehyde-induced nociception in vivo and blocks cold- and mustard oil-induced activation of mouse TRPA1 but not capsaicin-induced activation demonstrating selectivity vs TRPV1. AP-18 was unable to block activation of TRPV1, TRPV2, TRPV3, TRPV4 or TRPM8 at concentrations up to 50μM. It reverses CFA-induced mechanical hyperalgesia in mice.
Product Details
| Alternative Name: | 4-(4-Chlorophenyl)-3-methylbut-3-en-2-oxime |
| |
| Formula: | C11H12CINO |
| |
| MW: | 209.7 |
| |
| CAS: | 55224-94-7 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | White solid. |
| |
| Solubility: | Soluble in DMSO (>25mg/ml); ethanol (25mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Anoxia/reoxygenation enhances spontaneous contractile activity via TRPA1 channel and COX2 activation in isolated rat whole bladder: T. Anraku, et al.; Neurourol. Urodyn.
41, 1692 (2022),
Abstract;
The role of TRPA1 in muscle pain and mechanical hypersensitivity under inflammatory conditions in rats: J. Asgar, et al.; Neuroscience
310, 206 (2015),
Application(s): Cell Culture,
Abstract;
A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition: M. Petrus, et al.; Mol. Pain
3, 40 (2007),
Abstract;
Full Text
